WEDNESDAY, Feb. 22 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel gave its blessing Wednesday to a highly anticipated weight loss pill that had been rejected by health advisers once before.
Read more...
WEDNESDAY, Feb. 22 (HealthDay News) -- The U.S. Food and Drug Administration plans to take a second look at the weight loss pill Qnexa on Wednesday, after initially rejecting it because of concerns about heart problems and possible birth defects.
Read more...
Vivus Inc. (VVUS) ’s weight-loss pill Qnexa won the backing of a U.S. advisory panel as the company seeks to gain approval for the first new obesity drug in 13 years.
Read more...
VANCOUVER — Weight loss is not as simple as eating less and exercising more, and for those who struggle to shed the pounds, a new equation may offer some help.
Read more...
In a reversal, an FDA advisory committee backs the weight-loss drug Qnexa despite health risks after its maker, Vivus, promises strict oversight. A panel of medical experts voted overwhelmingly Wednesday to endorse the controversial weight-loss drug Qnexa, clearing the way for the Food and Drug Administration to approve a new prescription obesity medication for the first time since 1999.
Read more...
An experimental obesity drug from Vivus Inc won a U.S. panel's support on Wednesday, raising hopes regulators would approve a weight-loss pill for the first time in 13 years.
Read more...
Vivus Inc.’s weight-loss pill Qnexa won the backing of a U.S. advisory panel as the company seeks to gain approval for the first new obesity drug in 13 years.
Read more...
